menu ☰
menu ˟

Disease factors predict outcomes across treatments for BRAF V600-mutated melanoma

11 Oct 2018
Baseline lactate dehydrogenase level, ECOG performance status and disease burden strongly predicted PFS and OS among patients with BRAF V600-mutant metastatic melanoma treated with BRAF or MEK inhibitors, according to a retrospective and exploratory ...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.